ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Rare-disease drugmaker Alexion Pharmaceuticals will cut 20% of its workforce, about 600 jobs, and move its headquarters to Boston, leaving about 450 positions behind in New Haven, Conn. The move comes amid controversy over aggressive sales practices for Alexion’s drug Soliris, which treats rare blood diseases, that led to the ousting of its CEO. The downsizing includes the shuttering of a plant in Smithfield, R.I., and the end of partnerships with Moderna Therapeutics and Arbutus Biopharma.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X